Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Paul Capital Royalty Acquisition Fund was a specialized investment vehicle managed by Paul Capital that pioneered the acquisition of royalty interests in the healthcare sector. The fund provided non-dilutive financing to biotechnology companies, academic institutions, and inventors by purchasing future royalty streams from approved or late-stage pharmaceutical products and medical devices. In 2006, the healthcare royalty team transitioned out of Paul Capital to establish HealthCare Royalty Partners (HCRP), an independent firm that continues this investment strategy. During its operation, the fund built a diverse portfolio of royalty interests in numerous blockbuster therapies across multiple therapeutic categories.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Paul Capital Royalty Acquisition Fund.